2025-03-31 18:40:03
Latest Post
NHPC commissions 3 units of Parbati-II HE project
ixigo announces APRIL FULL REFUND SALE for 1st April - 100 Lucky Travellers To Win 100% Refund on Flight Bookings
Engineers India Ltd receives orders worth Rs. 245 crores
Blue Star appoints Mohit Sud as Group President, Unitary Cooling Products 
Jyoti Ltd receives Rs. 108.17 crores IT demand notice for AY 2020-21
Stock Report
Bliss GVS Pharma Q4FY22 consolidated PAT rises to Rs. 19.63 crores
Posted On : 2022-04-30 21:51:16( TIMEZONE : IST )
Bliss GVS Pharma Limited has reported Consolidated financial results for the period ended March 31, 2022.
Financial Results (Q4 FY2022) - QoQ Comparison
The company has reported total income of Rs. 179.2518 crores during the period ended March 31, 2022 as compared to Rs. 222.2942 crores during the period ended December 31, 2021.
The company has posted net profit / (loss) of Rs. 19.6320 crores for the period ended March 31, 2022 as against net profit / (loss) of Rs. -50.1122 crores for the period ended December 31, 2021.
The company has reported EPS of Rs. 1.87 for the period ended March 31, 2022 as compared to Rs. -4.74 for the period ended December 31, 2021.
| Financials | Q4 FY2022 | Q3 FY2022 | % Change |
| Total Income | ₹ 179.2518 crs | ₹222.2942 crs |  -19.36% |
| Net Profit | ₹19.6320 crs | ₹-50.1122 crs |  139.18% |
| EPS | ₹1.87 | ₹-4.74 | 139.45% |
Financial Results (Q4 FY2022) - YoY Comparison
The company has reported total income of Rs. 179.2518 crores during the period ended March 31, 2022 as compared to Rs.138.3801 crores during the period ended March 31, 2021.
The company has posted net profit / (loss) of Rs.19.6320 crores for the period ended March 31, 2022 as against net profit / (loss) of Rs.6.2421 crores for the period ended March 31, 2021.
The company has reported EPS of Rs.1.87 for the period ended March 31, 2022 as compared to Rs.0.59 for the period ended March 31, 2021.
| Financials | Q4 FY2022 | Q4 FY2021 | % Change |
| Total Income | ₹ 179.2518 crs | ₹138.3801 crs | 29.54% |
| Net Profit | ₹19.6320 crs | ₹6.2421 crs | 214.51% |
| EPS | ₹1.87 | ₹0.59 | 216.95% |
Financial Results (Year Ended FY2022) - YoY Comparison
The company has reported total income of Rs.778.9460 crores during the Financial Year ended March 31, 2022 as compared to Rs.597.4298 crores during the Financial Year ended March 31, 2021.
The company has posted net profit / (loss) of Rs.15.0402 crores for the Financial Year ended March 31, 2022 as against net profit / (loss) of Rs.68.4909 crores for the Financial Year ended March 31, 2021.
The company has reported EPS of Rs.1.43 for the Financial Year ended March 31, 2022 as compared to Rs.6.49 for the Financial Year ended March 31, 2021.
| Financials | Year Ended FY2022 | Year Ended FY2021 | % Change |
| Total Income | ₹778.9460 crs | ₹597.4298 crs | 30.38% |
| Net Profit | ₹15.0402 crs | ₹68.4909 crs | -78.04% |
| EPS | ₹1.43 | ₹6.49 | -77.97% |
Shares of Bliss GVS Pharma Limited was last trading in BSE at Rs. 80.40 as compared to the previous close of Rs. 82.50. The total number of shares traded during the day was 143591 in over 2057 trades.
The stock hit an intraday high of Rs. 83.55 and intraday low of 80.00. The net turnover during the day was Rs. 11796837.00.
